Skip to content
buyWeak

Michael T. Constantino bought $20k of HUMA

director at Humacyte, Inc.. 4,600 shares at an average of $4.39, traded Dec 4, 2024, filed Dec 4, 2024.

Conviction score
21
Value
$20k
4,600 shares
Holdings after
16,950
+37% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $20k at market
    0
  • Relative to holdings
    Holdings up 37%
    +6
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HUMAOct 9, 2026 · close 0.41
Since filing Dec 4, 2024: -90.9%SPY +31.1% · excess -121.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001818382-24-000216, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 4, 2024POpen-market purchase
Common Stock
+4,600$4.39$20k16,950Dec 4, 2024

Related signals

Other insiders at Humacyte, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
HUMAbuy
Humacyte, Inc.
Keith Anthony Jones
director
$5,620
10,000 shares
+25%
43Moderate
HUMAbuy
Humacyte, Inc.
Michael T. Constantino
director
$20k
16,000 shares
+94%
18Weak
HUMAbuy 2
Humacyte, Inc.
Brady W Dougan
director
$7,979
1,797 shares
+1%
28Weak
HUMAbuy 2
Humacyte, Inc.
Laura E Niklason
President, CEO and Director
$7,979
1,797 shares
+1%
58Moderate
HUMAsell 2
Humacyte, Inc.
Brady W Dougan
director
$6.6M
1,500,000 shares
-46%
68Notable
HUMAsell 2
Humacyte, Inc.
Laura E Niklason
President, CEO and Director
$6.6M
1,500,000 shares
-46%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael T. Constantino bought $20k of HUMA | InsiderTell